Could your body clock affect rare inflammatory disease?
NCT ID NCT06544018
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether people with CAPS (a rare genetic inflammatory condition) have disrupted circadian rhythms—the body's natural day-night cycle. Researchers will measure melatonin levels and track activity with a watch in 30 participants (patients and healthy household members). The goal is to understand how the internal clock may influence CAPS symptoms, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal how the body's internal clock influences CAPS symptoms, pointing toward new ways to manage the disease.
- What could go wrong
- This is a small observational study (30 participants) that measures biomarkers, not a treatment trial. It may not lead to direct therapies or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Feb 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
---Inclusion Criteria: Patient with CAPS group : * Patients aged 6 and over * Participant with CAPS confirmed by NLRP3 genetic analysis * Weight greater than or equal to 25 Kg * Parents/guardians who have been informed of the study and have signed a consent form. * Patient affiliated to a social security scheme Control group (healthy participant): * Participant aged 6 and over * Weight greater than or equal to 25 Kg * Participant living in the same household as a subject with CAPS genetically confirmed by NLRP3 analysis and included in the protocol * Participant with no CAPS (a priori) who consents to NLRP3 genetic analysis * Parents/guardians who have been informed of the study and have signed a consent form. * Participant who has been informed of the study and has agreed to take part * Participant affiliated to a social security scheme * Exclusion Criteria : Patient with CAPS group : * Patients with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin). * Patients with sleep apnea syndrome * Patients working regular night shifts or alternating day and night shifts * Pregnant or breast-feeding women * Parents with an infant under 6 months of age * Patient participating in another interventional drug study * Deprivation of civil rights (curators, guardianship, safeguard of justice) Control group (healthy participant): * Participants with a chronic illness (ALD beneficiaries) * Participants with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin) * Participants working regular night shifts or alternating day and night shifts * Pregnant or breast-feeding women * Parents with an infant under 6 months of age * Participant participating in another interventional drug study * Deprivation of civil rights (curators, guardianship, safeguard of justice)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cinca syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Claude Huriez (CHU de Lille)
NOT_YET_RECRUITINGLille, 59037, France
-
Hôpital Edouard Herriot (HCL)
NOT_YET_RECRUITINGLyon, 69437, France
-
Hôpital Femme-Mère-Enfant (HCL)
RECRUITINGBron, 69677, France
-
Hôpital Kremlin-Bicêtre (AP-HP)
NOT_YET_RECRUITINGParis, 94270, France
-
Hôpital Tenon (AP-HP)
NOT_YET_RECRUITINGParis, 75020, France
-
Hôpital de la Croix-Rousse (HCL)
NOT_YET_RECRUITINGLyon, 69004, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.